Cargando…

A Novel High-Throughput 3D Screening System for EMT Inhibitors: A Pilot Screening Discovered the EMT Inhibitory Activity of CDK2 Inhibitor SU9516

Epithelial-mesenchymal transition (EMT) is a crucial pathological event in cancer, particularly in tumor cell budding and metastasis. Therefore, control of EMT can represent a novel therapeutic strategy in cancer. Here, we introduce an innovative three-dimensional (3D) high-throughput screening (HTS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arai, Kazuya, Eguchi, Takanori, Rahman, M. Mamunur, Sakamoto, Ruriko, Masuda, Norio, Nakatsura, Tetsuya, Calderwood, Stuart K., Kozaki, Ken-ichi, Itoh, Manabu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021355/ https://www.ncbi.nlm.nih.gov/pubmed/27622654 http://dx.doi.org/10.1371/journal.pone.0162394

Ejemplares similares

Time-lapse imaging assay using the BioStation CT: A sensitive drug-screening method for three-dimensional cell culture
por: Sakamoto, Ruriko, et al.
Publicado: (2015)

SCAND1 Reverses Epithelial-to-Mesenchymal Transition (EMT) and Suppresses Prostate Cancer Growth and Migration
por: Eguchi, Takanori, et al.
Publicado: (2022)

A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptor
por: Lotz-Jenne, Carina, et al.
Publicado: (2016)

Tumor Budding: The Name is EMT. Partial EMT.
por: Grigore, Alexandru Dan, et al.
Publicado: (2016)

Phenotypic chemical screening using a zebrafish neural crest EMT reporter identifies retinoic acid as an inhibitor of epithelial morphogenesis
por: Jimenez, Laura, et al.
Publicado: (2016)

High content screening identifies monensin as an EMT-selective cytotoxic compound
por: Vanneste, Marion, et al.
Publicado: (2019)

Forward Genetic Screens as Tools to Investigate Role and Mechanisms of EMT in Cancer
por: Gasparics, Ákos, et al.
Publicado: (2022)

NMI and EMT
por: Samant, Rajeev S., et al.
Publicado: (2014)

A zebrafish embryo screen utilizing gastrulation identifies the HTR2C inhibitor pizotifen as a suppressor of EMT-mediated metastasis
por: Nakayama, Joji, et al.
Publicado: (2021)

EMT or EMT-Promoting Transcription Factors, Where to Focus the Light?
por: Ansieau, Stéphane, et al.
Publicado: (2014)

Meta-Analysis of EMT Datasets Reveals Different Types of EMT
por: Liang, Lining, et al.
Publicado: (2016)

Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines
por: Ji, Wonjun, et al.
Publicado: (2020)

The 'alternative' EMT switch
por: Klingbeil, Pamela, et al.
Publicado: (2011)

EMT in immuno-resistance
por: Terry, Stéphane, et al.
Publicado: (2015)

EMT and tumor metastasis
por: Heerboth, Sarah, et al.
Publicado: (2015)

News and views on EMT Fra-1 controls EMT in mammary epithelial cells
por: Bakiri, Latifa, et al.
Publicado: (2015)

EMT-Regulome: a database for EMT-related regulatory interactions, motifs and network
por: Zhao, Zhangxiang, et al.
Publicado: (2017)

Competitive endogenous RNA is an intrinsic component of EMT regulatory circuits and modulates EMT
por: Liu, Yuwei, et al.
Publicado: (2019)

The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas
por: Sánchez-Tilló, Ester, et al.
Publicado: (2023)

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
por: Kitai, Hidenori, et al.
Publicado: (2016)

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
por: Verdura, Sara, et al.
Publicado: (2022)

Machine Learning-Based Virtual Screening for the Identification of Cdk5 Inhibitors
por: Di Stefano, Miriana, et al.
Publicado: (2022)

Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment
por: Eguchi, Takanori, et al.
Publicado: (2018)

Virtual Screening on Marine Natural Products for Discovering TMPRSS2 Inhibitors
por: Mahmudpour, Mehdi, et al.
Publicado: (2021)

Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT
por: Parvani, Jenny G, et al.
Publicado: (2013)

The EMT-activator ZEB1 induces bone metastasis associated genes including BMP-inhibitors
por: Mock, Kerstin, et al.
Publicado: (2015)

miR-655 Is an EMT-Suppressive MicroRNA Targeting ZEB1 and TGFBR2
por: Harazono, Yosuke, et al.
Publicado: (2013)

Targeting of polycombs to DNA in EMT
por: Battistelli, Cecilia, et al.
Publicado: (2017)

The EMT spectrum and therapeutic opportunities
por: Voon, Dominic C., et al.
Publicado: (2017)

Sirtuins and Hypoxia in EMT Control
por: Aventaggiato, Michele, et al.
Publicado: (2022)

Epithelial–Mesenchymal Transition (EMT)
por: Manfioletti, Guidalberto, et al.
Publicado: (2023)

ODP562 ZnT5 Involvement in EMT in Breast Cancer
por: Miki, Yasuhiro, et al.
Publicado: (2022)

Author Correction: Competitive endogenous RNA is an intrinsic component of EMT regulatory circuits and modulates EMT
por: Liu, Yuwei, et al.
Publicado: (2019)

Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer
por: Padhye, Aparna, et al.
Publicado: (2021)

Mycobacterium tuberculosis virulence inhibitors discovered by Mycobacterium marinum high-throughput screening
por: Tükenmez, Hasan, et al.
Publicado: (2019)

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors
por: van der Noord, Vera E., et al.
Publicado: (2023)

Epithelial-Mesenchymal Transition (EMT): The Type-2 EMT in Wound Healing, Tissue Regeneration and Organ Fibrosis
por: Marconi, Guya D., et al.
Publicado: (2021)

Heterogeneity and plasticity of epithelial–mesenchymal transition (EMT) in cancer metastasis: Focusing on partial EMT and regulatory mechanisms
por: Li, Dandan, et al.
Publicado: (2023)

HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer
por: Rumman, Marufa, et al.
Publicado: (2016)

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma
por: MAHGOUB, T., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gnah34v6ihj3k69ogn8bsdte83